MC
STRO icon

Merck & Co’s Sutro Biopharma STRO Stock Holding History

Merck & Co’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.04M Hold
272,351
– – 1.72% 7
2026
Q1 		$6.78M Hold
272,351
– – 1.94% 8
2025
Q4 		$3.15M Hold
272,351
– – 1.14% 7
2025
Q3 		$2.37M Hold
272,351
– – 1.04% 7
2025
Q2 		$1.94M Hold
272,351
– – 0.9% 7
2025
Q1 		$1.77M Hold
272,351
– – 1.08% 7
2024
Q4 		$5.01M Buy
+272,351
New +$8.31M 1.94% 6

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Merck & Co's STRO Position: Q2 2026 in Review

Merck & Co held its Sutro Biopharma (STRO) position steady in Q2 2026 at 272,351 shares worth $9.04M. The position accounts for 1.72% of the portfolio, ranked #7.

Merck & Co first reported a position in STRO in Q4 2024 and has held it in 7 quarters since. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Merck & Co held 272,351 shares of Sutro Biopharma worth $9.04M as of Q2 2026.
  • Merck & Co left its Sutro Biopharma share count unchanged in Q2 2026.
  • Sutro Biopharma made up 1.72% of Merck & Co's portfolio in Q2 2026, its #7 holding.
  • Merck & Co first reported a position in Sutro Biopharma in Q4 2024 and has held it in 7 quarters since.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Merck & Co's 13F filing for Q2 2026, filed 7 Aug 2026.